βig-h3/TGF-βi is a secreted protein capable of binding to both extracellular matrix and cells.
Introduction
Type 1 diabetes (T1D) is a polygenic autoimmune disease characterized by smoldering inflammatory response directed against the insulin-producing β islet cells of the pancreas.
Both CD4
+ and CD8 + T cells are involved in the destruction of β cells (shed by a prior insult).
CD4
+ T cells are insulin reactive and CD8 + T cells play a major role as β cells killers (1, 2).
While both in vitro and in vivo evidence point a role for regulatory T cells in the T-cell mediated regulation controlling diabetes in mouse models (3) , the influence of the inflammatory environment within which they function remains poorly understood. The crosstalk between the inflammatory milieu and the immune response during insulitis is likely to be communicated in large part through the extracellular matrix (ECM). βig-h3 (also known as TGFβi) is a secreted protein found in the ECM and it has an N-terminal secretory signal (aa 1-23), four FAS1 homologous internal domains, and a cell attachment site (RGD) at its C terminus (4) . βigh3 binds to the ECM through interaction of YH motif in its FAS1 domains with collagens I, II, IV and VI (5, 6) . Its FAS1 domain interacts its α3β1, αVβ3 and αVβ5
integrins on cell surface. Previous studies demonstrated that recombinant βig-h3 could preserve the integrity and enhance the function of cultured pancreatic islet cells (7) .
Conversely, βig-h3 KO islets function was compromised in vivo after transplantation in diabetic recipients (8) . These studies point out that βig-h3 might play an active role in the protection of β-cell against T cell cytotoxic insult in T1D. The effect of βig-h3 on T cell function and activation relative to its roles in islet β-cell-ECM destruction in T1D in mice has never been investigated and it's the focus of our project.
Flow cytometry analysis
Cells isolated from draining lymph node or perfused pancreata were stained using following antibodies CD8-V450, CD4-V500, CD44 A700 (BD Biosciences) and CD69 FITC and FlowJo (Tree Star, Inc.).
Western Blot
Proteins were extracted with a RIPA buffer, thirty µg of protein were separated using SDS-PAGE and transferred to a nitrocellulose membrane (Amersham). Primary antibodies (antiLck, Cell Signaling; anti-pSrc pY416 -which recognizes Lck on pY394, Cell Signaling; antipLck pY505, Cell Signaling; mouse anti-Actin, Sigma) were incubated overnight, followed by HRP-conjugated secondary antibodies (Amersham) prior detection using an ECL solution (Pierce.). Image Lab (Biorad) was use for subsequent quantification.
Immunoflurescence and confocal microscopy
Triple immunofluoresent staining (IF) was carred out on 3-µm-thick paraffin pancreas section. Sections were rehydrated and subjected to antigen retrieval in an unmasking solution (Vector H 3300). Tissues sections were incubated overnight with anti-TGFβi (rabbit, Sigma),
anti-Insulin (guinea-pig, Dako) and anti-Glucagon (mouse, Sigma) primary antibodies.
Secondary fluorescence-conjugated antibody (Jackson-ImmunoResearch) were incubated 1h
prior mounting using a DAPI-Vectashield Mounting medium (Vectorlabs). Cell IF was done on cytospined-cells fixed in 4% paraformaldehyde prior the permeabilization. Primary 6 antibodies, anti-TCRβ (Becton Dickinson) and phospho-Lck pY505 (Cell Signaling) were incubated overnight and subsequently detected using specific anti-Fab'2-Alexa 488, 647 and 555 (Molecular Probes) secondary antibodies prior mounting. All staining were acquired on a LSM780 Zeiss confocal microscope and subsequently analyzed using Zen software (Zeiss).
Method used for colocalization quantifications was previously described (11) .
Statistical analysis
P values were calculated with Student's t test, (GraphPad Prism) as specified in figure legends. *P < 0.05; **P < 0.01; ***P < 0.001.
Results

β β β βig-h3 inhibits T cell activation
To study a direct role of βig-h3 on T-cells, we isolated T-cells from WT-mice lymph nodes and treated them using a human recombinant βig-h3 for 24 h prior their activation with different doses of anti-CD3 antibody (Fig. 1) . Since TCR avidity modulates T cell activation (12) and that autoreactive T cell respond to low affinity and avidity peptides, we compared the ability of CD8 + T cells to respond to high (1000 ng/ml), intermediate (100 ng/ml) and low concentrations (10 ng/ml) of anti-CD3 after treatment or not with recombinant βigh3. We show that at high and intermediate concentration of anti-CD3, βig-h3 did not modulate the activation of CD8 + T-cell following TCR engagement as shown by the activation markers CD69 and CD44. In contrast, βig-h3 was able to inhibit subsequent low dose CD8 + (as well as CD4 + T cell) activation as shown by the significant reduction of CD69 and CD44 expression ( Fig. 1 A, B, Supplementary Fig. 1A ). Furthermore, both CD8 + and CD4 + T cells treated with βig-h3 for 24h displayed reduced production of cytotoxic intracellular IFN and Granzyme B (Fig. 1C,D, Supplementary Fig. 1A ). In order to explore the role of βig-h3 in pathological condition of T1D, we extracted T cells from 6 months old diabetic NOD mice and treated them with recombinant βig-h3 for 24h before assessing their production of IFNγ. We found βig-h3 pretreated pancreatic T-cells from diabetic NOD mice to produce significantly lower intracellular IFNγ ( Supplementary Fig. 1B ). Therefore, βig-h3 was able to reduce the production of inflammatory cytokines by diabetogenic T cells ex vivo. Thus, together these results point out an important immunomodulatory role for βig-h3 protein in the activation and production of inflammatory cytokines by T cells. β β β βig-h3 inhibits early TCR signaling βig-h3 has been reported to signal from the extracellular environment through αvβ3 integrins (13) . Interestingly, integrin signaling has been reported to share early TCR signaling molecules (14, 15) . Therefore, we investigated the effect of βig-h3 signaling on the activation of early actors of the TCR signaling. Initiation of the TCR signaling pathway relies on the induction of tyrosine protein phosphorylation of the kinase Lck (16, 17) . The regulation of the enzymatic activity of this Src family tyrosine kinase is tightly controlled by conformational changes mainly relying on phosphorylation and dephosphorylation on two regulatory tyrosine residues Y505 and Y394 (18, 19) . In resting T cells, as previously reported (20), a larger percentage of Lck was phosphorylated on Y394 and thus was present under its activated conformation ( Fig. 2 A) . However, in clear contrast, in βig-h3 treated CD8 + T cells were mainly phosphorylated on Y505, implying that βig-h3 signaling influenced the Lck conformation-equilibrium towards its inactive state ( Fig. 1 ) in resting not-treated T cells (Fig. 2 C) . In contrast, after TCR engagement with anti-CD3, pY505 colocalisation with the TCR was significantly diminished (Fig. 2 C and Supplementary Fig. 1 ). In βig-h3 treated cell, the colocalisation of the Lck Y505 with the TCR was similar in resting cells and after TCR engagement (around 58%) ( Supplementary Fig. 2 and Fig. 2C ), suggesting that βig-h3
signaling interfere with T cell activation. showed similar immune infiltration to NOD normoglycemic non-diabetic age matched females (Fig. 1A) suggesting that local immunosuppression mechanism might be involved.
Immunofluorescence analysis showed that βig-h3 was expressed in pancreatic islets in normal mice as well as in normoglycemic non-diabetic NOD mice (Fig. 1A, B) . We found βig-h3 expressed in the cytoplasm of both α-and β-cells as well as in the extracellular islet compartment (Figure 1 A, B arrows). In contrast, in type 1 diabetic islets, βig-h3 expression was reduced at both mRNA ( Supplementary Fig. 2 ) and protein level ( Fig. 1 A, B) . Only α-cells retained expression of βig-h3 in mouse diabetic individuals ( Fig. 1 A, B) . We also analyzed human pancreas sections of type 1 (n=2) and type 2 diabetes (T2D) (n=2) patients and non-diabetic patients (n=2). In human pancreas, βig-h3 was expressed only by β cells and in the extracellular matrix in T2D and non-diabetic patients. T1D patients show very reduced βig-h3 expression (Fig. 1C) . Together, these data suggest that pancreatic islet expression of βig-h3 might play a role in the susceptibility to develop T1D. Figure 4A ). In contrast to control-Ab-treated mice, βig-h3 depleted animals develop diabetes to suboptimal dose of STZ as measured by significant increase of glycaemia ( Figure 4B ). Next, we isolated islets from WT-C57Bl/6 mice and cultured them in presence of a neutralizing anti-βig-h3 antibody prior their coculture with STZ-diabetic isolated T-cells. As shown in Supplementary Fig. 4B , we found 24h treatment with anti-βig-h3 to significantly decreased the amount of βig-h3 protein detected in the supernatant of cultured islets. T-cells extracted from STZ-diabetic pancreas were CFSEstained and added to the islet culture for 48 hours prior the quantification of intracellular production of Granzyme B and IFNγ by flow cytometry (Fig. 4C) . While the proliferation of T-cell was not affected by the βig-h3 antibody treatment of islet cells (Fig. 4D) , we found the production of Granzyme B and IFNγ to be significantly increased in βig-h3 depleted-islet conditions (Fig. 4E, F) , suggesting that physiological release of the protein by the islets was able to inhibit T-cell cytotoxic cytokines production. In order to investigate the physiological relevance of the repression of the T-cell response in vitro, we used in vivo diabetes transfer model. T-cells from pancreas of diabetic mice (STZ-induced T1D) were treated with recombinant βig-h3 and then intravenously injected in immunodeficient Rag2 KO congenic mice. Mice were sacrificed 2 days after T-cell injection and islets infiltration by Granzyme B + cells assessed by immunofluorescence (Fig.4I, Supplementary Fig. 4C ). Measurements of glycaemia showed that βig-h3 pre-treated T-cells were unable to induce diabetes as compared to not-treated T-cells (Fig. 4H) . Although equivalent percentages of CD45 + cells were detected by FACS in recipient's pancreas 10 days post-injection (Fig. 4J) , T-cells preatreated with βig-h3 showed lower level of CD69 (Fig. 4K ) and less production of IFNγ and CD107a (Fig. 4L, M) . Thus, these findings reveal an important role of βig-h3 in inhibiting diabetogenic T-cell activity in vitro and in vivo.
Discussion
A major goal of T1D research is to restore beta cell function while eliminating diabetogenic T cells by immunotherapy in the hope of achieving insulin independence. To develop an effective immunotherapy, there must be a continued effort on defining the molecular basis that underlies T cell response to pancreatic islet antigens in T1D. Therefore, identifying new targets involved in the protection against cytotoxic T lymphocyte attack might be important for defining new therapy hints. We show here that βig-h3, a protein of the islet ECM, is able to repress diabetogenic T cell activation by interfering with early actors of the TCR signaling pathway, ie Lck. This alteration has major consequences on T cell expression of activation markers (CD69 and CD44) upon TCR engagement, as well as production of IFNγ and Granzyme B. Previous finding identified βig-h3 as vital trophic factor promoting islet survival, function and regeneration (7) . We demonstrate that in addition to its trophic support to pancreatic islet, βig-h3 plays an active role in inhibiting the activation T cell activation to low concentration of antigen or autoreactive T cells. Signaling through integrins has been described to only facilitate T-cell activation by lowering an activation threshold without qualitatively changing the T-cell response (22) . Our results show that βig-h3 signaling through T cell surface integrins was able to inhibit TCR activation by phosphorylating Lck on inhibitory tyrosine Y505. Previous studies showed that Lck plays an important role in regulating autoimmunity since it has been described that specific deficiency of this kinase in T cells of patients with type 1 diabetes (23) in the pancreatic islets (Fig. 3 B) and that the expression is lost in hyperglycemic aged match diabetic NOD mice. Since the immune infiltration was similar, this data suggest that βig-h3
expression might contribute as a protective shield against cytotoxic T cell attack. Our experimental findings reconsider the conventional understanding of "cytotoxic" T cellinduced β cell death in T1D in order to take into account β cell "matrix" as critical component of T1D pathogenesis. Studies of the βig-h3 impact on islet-specific T cell in from human peripheral blood T1D to expression in diabetic human pancreas will further elucidate whether this protein is also a key target of immune tolerance in human T1D. 
